%0 Journal Article %T Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? %A Green, John A. %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? %K %X Epidermal growth factor (EGFR) M+ non-small cell lung cancer (NSCLC) accounts for about 10% of non-squamous NSCLC in Europe and North America and as much as 40% in women in Asian countries (1). %U https://jtd.amegroups.org/article/view/24410 %P S3837-S3839 %@ 2077-6624